Market Access Biotech's next growth cycle: Renewed confidence comes with c... Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.
Market Access Seeing is investing: The power of visuals at every stage of ... Whether your biotech start-up is in its infancy or on the verge of a major acquisition, how you communicate your work – through clear messaging and impactful visuals – can play a pivotal ro
Views & Analysis Why does UK biotech struggle to generate leaders? Can the UK emulate America's culture of biotech entrepreneurship?
News Novartis raises forecasts for three key growth products Novartis raises sales expectations for three growth products – Kesimpta, Scemblix, and Leqvio – by $4bn as it sets a 5% midterm revenue growth target.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.